CA2670157A1 - Delivery system for risperidone - Google Patents
Delivery system for risperidone Download PDFInfo
- Publication number
- CA2670157A1 CA2670157A1 CA002670157A CA2670157A CA2670157A1 CA 2670157 A1 CA2670157 A1 CA 2670157A1 CA 002670157 A CA002670157 A CA 002670157A CA 2670157 A CA2670157 A CA 2670157A CA 2670157 A1 CA2670157 A1 CA 2670157A1
- Authority
- CA
- Canada
- Prior art keywords
- risperidone
- drug
- skin
- inner compartment
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 90
- 229960001534 risperidone Drugs 0.000 title claims abstract description 84
- 239000005038 ethylene vinyl acetate Substances 0.000 claims abstract description 44
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 229920000642 polymer Polymers 0.000 claims abstract description 32
- 238000009472 formulation Methods 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 14
- 238000013265 extended release Methods 0.000 claims abstract description 12
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 24
- 238000001125 extrusion Methods 0.000 claims description 21
- 229920001169 thermoplastic Polymers 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 description 55
- 239000003814 drug Substances 0.000 description 55
- 239000011162 core material Substances 0.000 description 35
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 30
- 229940117958 vinyl acetate Drugs 0.000 description 23
- 239000006213 vaginal ring Substances 0.000 description 19
- 239000000835 fiber Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- 239000008187 granular material Substances 0.000 description 15
- 238000012377 drug delivery Methods 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- 238000009792 diffusion process Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 229940044953 vaginal ring Drugs 0.000 description 8
- 208000034423 Delivery Diseases 0.000 description 7
- -1 alkenyl sulfate Chemical class 0.000 description 7
- 230000009677 vaginal delivery Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- MXDOOIVQXATHKU-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXDOOIVQXATHKU-RYVPXURESA-N 0.000 description 1
- 229940122863 Acrosin inhibitor Drugs 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 101000998633 Drosophila funebris Male accessory gland serine protease inhibitor Proteins 0.000 description 1
- 229920003345 Elvax® Polymers 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920003351 Ultrathene® Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical class 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940115044 nuvaring Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124598.1 | 2006-11-22 | ||
| EP06124598 | 2006-11-22 | ||
| PCT/EP2007/062628 WO2008062009A1 (en) | 2006-11-22 | 2007-11-21 | Delivery system for risperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2670157A1 true CA2670157A1 (en) | 2008-05-29 |
Family
ID=37898528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002670157A Abandoned CA2670157A1 (en) | 2006-11-22 | 2007-11-21 | Delivery system for risperidone |
| CA002670454A Abandoned CA2670454A1 (en) | 2006-11-22 | 2007-11-21 | Delivery system for a non-steroidal non-ionized hydrophilic drug |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002670454A Abandoned CA2670454A1 (en) | 2006-11-22 | 2007-11-21 | Delivery system for a non-steroidal non-ionized hydrophilic drug |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100203104A1 (enExample) |
| EP (2) | EP2094348A1 (enExample) |
| JP (2) | JP2010510286A (enExample) |
| CA (2) | CA2670157A1 (enExample) |
| MX (2) | MX2009005445A (enExample) |
| WO (2) | WO2008062008A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| US7858110B2 (en) | 2003-08-11 | 2010-12-28 | Endo Pharmaceuticals Solutions, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
| CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| GB0613333D0 (en) * | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) * | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| WO2008007098A2 (en) * | 2006-07-12 | 2008-01-17 | Controlled Therapeutics (Scotland) Ltd. | Drug delivery polymer with hydrochloride salt of clindamycin |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| CA2670157A1 (en) * | 2006-11-22 | 2008-05-29 | N.V. Organon | Delivery system for risperidone |
| WO2009129459A1 (en) * | 2008-04-18 | 2009-10-22 | Combinent Biomedical Systems, Inc. | Devices that include ethylene-vinyl acetate copolymers and methods of making and using same |
| AU2009298637B2 (en) * | 2008-09-30 | 2015-08-13 | Braeburn Pharmaceuticals, Inc. | Implantable device for the delivery of risperidone and methods of use thereof |
| WO2010105093A2 (en) * | 2009-03-12 | 2010-09-16 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
| PL2547332T3 (pl) | 2010-03-16 | 2019-07-31 | Titan Pharmaceuticals, Inc. | Heterogeniczne wyroby wszczepialne do podaży leku |
| US20170319833A1 (en) * | 2010-03-28 | 2017-11-09 | Evestra, Inc. | Intravaginal drug delivery device |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| DE102013011399A1 (de) | 2012-07-31 | 2014-02-06 | Amw Gmbh | Implantat mit Risperidon |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| US10406336B2 (en) * | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| AU2019275406B2 (en) | 2018-05-24 | 2024-11-14 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| WO2019226519A1 (en) * | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| WO2022231930A1 (en) | 2021-04-26 | 2022-11-03 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016251A (en) * | 1972-08-17 | 1977-04-05 | Alza Corporation | Vaginal drug dispensing device |
| US4469671A (en) * | 1983-02-22 | 1984-09-04 | Eli Lilly And Company | Contraceptive device |
| GB9326255D0 (en) * | 1993-12-23 | 1994-02-23 | Roussel Lab Ltd | Medical device for the prevention and treatment of cancer |
| US6544546B1 (en) * | 1995-07-04 | 2003-04-08 | Akzo Nobel, N.V. | Ring-shaped devices |
| US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| CA2442281C (en) * | 2001-03-27 | 2010-06-08 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| US6887270B2 (en) * | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
| DE60325486D1 (de) * | 2002-08-30 | 2009-02-05 | Alza Corp | Prägbare und beschreibbare verbundrückschicht |
| CA2553254C (en) * | 2004-01-12 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8481079B2 (en) * | 2004-03-24 | 2013-07-09 | Merck Sharp & Dohme B.V. | Drug delivery system based on polyethylene vinylacetate copolymers |
| EP1824460B1 (en) * | 2004-11-10 | 2014-12-24 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
| CA2669833A1 (en) * | 2006-11-22 | 2008-05-29 | N.V. Organon | Vaginal delivery system for mirtazapine |
| CA2670157A1 (en) * | 2006-11-22 | 2008-05-29 | N.V. Organon | Delivery system for risperidone |
-
2007
- 2007-11-21 CA CA002670157A patent/CA2670157A1/en not_active Abandoned
- 2007-11-21 EP EP07822772A patent/EP2094348A1/en not_active Withdrawn
- 2007-11-21 CA CA002670454A patent/CA2670454A1/en not_active Abandoned
- 2007-11-21 WO PCT/EP2007/062626 patent/WO2008062008A1/en not_active Ceased
- 2007-11-21 MX MX2009005445A patent/MX2009005445A/es not_active Application Discontinuation
- 2007-11-21 MX MX2009005444A patent/MX2009005444A/es not_active Application Discontinuation
- 2007-11-21 EP EP07822774A patent/EP2094270A1/en not_active Withdrawn
- 2007-11-21 JP JP2009537627A patent/JP2010510286A/ja not_active Withdrawn
- 2007-11-21 US US12/515,882 patent/US20100203104A1/en not_active Abandoned
- 2007-11-21 WO PCT/EP2007/062628 patent/WO2008062009A1/en not_active Ceased
- 2007-11-21 US US12/515,897 patent/US20100104619A1/en not_active Abandoned
- 2007-11-21 JP JP2009537628A patent/JP2010510287A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009005444A (es) | 2009-06-02 |
| EP2094348A1 (en) | 2009-09-02 |
| MX2009005445A (es) | 2009-06-02 |
| JP2010510287A (ja) | 2010-04-02 |
| CA2670454A1 (en) | 2008-05-29 |
| US20100104619A1 (en) | 2010-04-29 |
| WO2008062009A1 (en) | 2008-05-29 |
| EP2094270A1 (en) | 2009-09-02 |
| JP2010510286A (ja) | 2010-04-02 |
| WO2008062008A1 (en) | 2008-05-29 |
| US20100203104A1 (en) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100203104A1 (en) | Delivery system for risperidone | |
| JP5380452B2 (ja) | ドラッグデリバリーシステム | |
| CA2524665C (en) | Drug delivery system | |
| AU2010224957B2 (en) | Zoo-technical drug delivery device | |
| TW201607563A (zh) | 藥物遞送系統 | |
| MXPA06010905A (es) | Sistema para el suministro de farmacos basados en copolimeros de polietileno y acetato de vinilo. | |
| US20100129425A1 (en) | Vaginal delivery system for mirtazapine | |
| WO2009141309A1 (en) | Delivery system for paliperidone | |
| KR20240130827A (ko) | 질내 링 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |